Ministry of Health
and Family Welfare
Daily Recoveries outnumber daily New Cases continuously for last 37 days
Posted On: 03 JAN
2021 9:55AM by PIB
This
has been made possible by the trend of recoveries exceeding new cases and low
number of fatalities per day which have ensured a total net reduction of the
Active Caseload.
29 States/UTs have less than 10,000
Active cases.
The
daily new recoveries recorded in the country have been more than the daily
cases registered since the last 37
days. The number of daily new cases in the last 24 hours is 18,177. While, 20,923 cases
recovered and discharged during the same duration.
The
rising recoveries have also improved the Recovery Rate to 96.16% today.
The
total recovered cases stand at 99,27,310. The gap
between Recovered Cases and Active Cases is increasing and presently stands at 96,80,090.
78.10% of the new recovered cases
are observed to be concentrated in 10 States/UTs.
Kerala
has reported the maximum number of single day recoveries with 4,985 newly
recovered cases. 2,110 people recovered in
81.81% of the new cases are
from 10 States and UTs.
Kerala
reported the highest daily new cases at 5,328. It is followed by
217 case fatalities have been
reported in the past 24 hours.
Ten
States/UTs account for 69.59% of new
deaths.
****
MV/SJ
HFW/COVID States data/3rd January2021/1
(Release ID: 1685736) Visitor Counter : 130
Ministry of Health
and Family Welfare
Press Statement by the Drugs Controller General of
India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine
Posted On: 03 JAN
2021 11:23AM by PIB
The
Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO)
met on 1st and 2nd January, 2021 and made recommendations in respect of
proposal for Restricted Emergency Approval of COVID-19 virus vaccine of M/s Serum
Institute of
The
Subject Expert Committee consists of domain knowledge experts from the fields
of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal
medicine, etc.
M/s
Serum Institute of India, Pune has presented a Recombinant Chimpanzee
Adenovirus vector vaccine (Covishield) encoding the SARS-CoV-2 Spike (S)
glycoprotein with technology transfer from AstraZeneca/Oxford University. The
firm submitted safety, immunogenicity and efficacy data generated on 23,745
participants aged ≥ 18 years or older from overseas clinical studies. The
overall vaccine efficacy was found to be 70.42%. Further, M/s Serum was granted
permission to conduct Phase-II/III clinical trial on 1600 participants within
the country. The firm also submitted the interim safety and immunogenicity data
generated from this trial and the data was found comparable with the data from
the overseas clinical studies. After detailed deliberations Subject Expert Committee
has recommended for the grant of permission for restricted use in emergency
situation subject to certain regulatory conditions. The clinical trial ongoing
within the country by the firm will continue.
M/s
Bharat Biotech has developed a Whole Virion Inactivated Corona Virus Vaccine
(Covaxin) in collaboration with ICMR and NIV (Pune), from where they received
the virus seed strains. This vaccine is developed on Vero cell platform, which
has well established track record of safety and efficacy in the country &
globally.
The
firm has generated safety and immunogenicity data in various animal species
such as mice, rats, rabbits, Syrian hamster, and also conducted challenge
studies on non-human primates (Rhesus macaques) and hamsters. All these data
has been shared by the firm with CDSCO. Phase I and Phase II clinical trials
were conducted in approx.800 subjects and the results have demonstrated that
the vaccine is safe and provides a robust immune response. The Phase III
efficacy trial was initiated in
The
Subject Expert Committee (SEC) has reviewed the data on safety and immunogenicity
of the vaccine and recommended for grant of permission for restricted use in
emergency situation in public interest as an abundant precaution, in clinical
trial mode, to have more options for vaccinations, especially in case of
infection by mutant strains. The clinical trial ongoing within the country by
the firm will continue.
M/s
Cadila Healthcare Ltd., has developed a Novel Corona Virus-2019-nCov-Vaccine
using DNA platform technology. The firm initiated Phase-I/II clinical trial in
M/s
Serum and M/s Bharat Biotech vaccines have to be administered in two doses. All
the three vaccines have to be stored at 2-8° C.
After
adequate examination, CDSCO has decided to accept the recommendations of the
Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech
are being approved for restricted use in emergency situation and permission is
being granted to M/s Cadila Healthcare for conduct of the Phase III clinical
trial.
****
MV/SJ
HFW/DCGI Media statement on COVID
Vaccine/3rd January2021/2
(Release ID: 1685761) Visitor Counter : 1238
No comments:
Post a Comment